Research Article

Supplemental *Bacillus subtilis* PB6 Improves Growth Performance and Gut Health in Broilers Challenged with *Clostridium perfringens*

Yan Liu,1 Song Zhang2,3, Zheng Luo3, and Dan Liu1

1State Key Laboratory of Animal Nutrition, College of Animal Science and Technology, China Agricultural University, Beijing, China
2Department of Animal Resource & Science, Dankook University, Cheonan, Choongnam 330–714, Republic of Korea
3Kemin (China) Technologies Co. Ltd., 25 Qinshi Road, Sanzao, Zhuhai 519040, China

Correspondence should be addressed to Dan Liu; liud@cau.edu.cn

Received 24 July 2021; Revised 15 September 2021; Accepted 29 September 2021; Published 27 October 2021

Copyright © 2021 Yan Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Clostridium perfringens* (CP) is the principal pathogenic bacterium of chicken necrotic enteritis (NE), which causes substantial economic losses in poultry worldwide. Although probiotics are known to provide multiple benefits, little is known about the potential effects of *Bacillus subtilis* (*B. subtilis*) application in preventing CP-induced necrotic enteritis. In this study, 450 male Arbor Acres broilers were divided into 5 experimental treatments: A: basal diet (control group); B: basal diet and CP challenge (model group); C: CP challenge+10 mg/kg enramycin (positive control group); D: CP challenge+4×10⁷ CFU/kg of feed *B. subtilis* PB6 (PB6 low-dosage group); and E: CP challenge+6×10⁷ CFU/kg of feed *B. subtilis* PB6 (PB6 high-dosage group). There were 6 replicate pens per treatment with 15 broilers per pen. The present research examined the effect of *Bacillus subtilis* PB6 (*B. subtilis* PB6) on growth performance, mRNA expression of intestinal cytokines and tight junctions, and gut flora composition in broilers challenged with CP. The entire experiment was divided into two phases: the non-CP challenge phase (d0–18) and the CP challenge phase (d18–26). PB6 did not increase the growth performance during the first stage, but the PB6 high-dosage group was found to have larger body weight gain and ADFI during the CP challenge stage. Feed supplementation with PB6 reduced the lesion score of challenged chicks, with increased tight junction-related gene expression (*occludin* and *ZO-1*) and decreased *TNF-α* expression compared with CP-infected birds. A decrease in the abundance of *Clostridium XI*, *Streptococcus*, and *Staphylococcus* was observed after CP infection (*P* < 0.05), while supplementation with PB6 restored the ileal microbial composition. In conclusion, administration of *B. subtilis* PB6 improved growth performance, enhanced intestinal barrier function, and mitigated intestinal inflammation/lesions, which might be due to its restoring effects on the ileal microbial composition in CP-challenged broilers.

1. Introduction

Necrotic enteritis (NE) is a serious bacterial disease in poultry that causes devastating financial losses. *Clostridium perfringens* (CP), an anaerobic gram-positive bacterium, is the major pathogen of NE. In fact, CP is one of the gut symbiotic bacteria of birds, and healthy birds normally harbor 10⁴ CFU/g of digesta in their intestine. CP is an opportunistic pathogen in some conditions, such as dietary nutrient risks (unbalanced diet formulation, antinutritional factors, and quality of raw materials), disease challenges (coccidiosis, infectious bursal virus), and inadequate management (high temperature), with increased proliferation to ~10⁷ to 10⁹ CFU/g of digesta [1], which leads to clinical signs of NE. In poultry production, subclinical NE leads to significant economic losses due to lesions in the small intestine, which in turn reduces body weight gain (BWG) and impairs the feed conversion ratio (FCR) [2]. Chickens are a reservoir of CP, and contaminated chicken products also represent a potential public food safety threat [3]. In human medicine,
Clostridial-contaminated food can be treated with surgical debridement and oral antibiotic therapy. However, antibiotic resistance among anaerobic bacteria, such as Clostridium species, is increasing worldwide [4]. Therefore, an efficient and natural method to overcome NE for chicken production in the postantibiotic age is warranted.

Probiotic supplementation has been demonstrated to be an efficient natural approach for regulating intestinal flora in humans and farm animals, which can act as follows: (a) a sustainer of the intestinal microflora ecosystem to maintain beneficial microflora colonization and inhibit pathogen proliferation, (b) a digestive booster to increase endogenous digestive enzyme activities and indigestion and reduce indigestible nutrient fermentation by depressing the activity of bacterial enzymes, and (c) a positive immune modulator by maintaining intestinal integrity [5]. Meanwhile, qualified probiotics have the capacity to overcome erratic elements, such as gastric acids, bile acids, endogenous proteases, and competition with other microorganisms. Consequently, Bacillus subtilis (B. subtilis) is a widely adopted probiotic bacterial species with many advantages. As a spore-forming facultative anaerobe, it has strong heat resistance and can last for 8 minutes at a high temperature of 113°C, which increases its possibility of survival during feed processing. At the same time, Bacillus spores have strong stress resistance and can survive in the gastrointestinal environment under harsh conditions, such as low pH and bile salts [6]. As a symbiotic bacterium, B. subtilis PB6 (ATCC-PTA 6737) has been proven to produce antibacterial substances and has a wide range of activities against numerous strains in vitro, including Campylobacter spp. and Clostridium spp. [7]. Moreover, research has demonstrated that supplementation with B. subtilis PB6 alleviates CP-induced gut lesions and also strengthens intestinal barrier function in broilers [8]. However, the potential effects of B. subtilis PB6 administration on gut microbiota composition and intestinal inflammatory damage in CP-challenged birds remain elusive. Here, we sought to determine the influence of B. subtilis PB6 administration on growth performance, lesion scores, intestinal tight junctions (TJs), proinflammatory cytokines, and gut microbiota composition in broilers challenged with CP.

2. Materials and Methods

2.1. Animals, Diets, and Housing. In total, 450 male Arbor Acres broilers were separated into 5 experimental groups, each of which was replicated 6 times for 15 broilers per replicate. The experiments were ethically approved by the Animal Care and Use Committee of China Agricultural University. All treatments were as follows: A: basal diet; B: basal diet+CP challenge; C: CP challenge+10 mg/kg enramycin; D: CP challenge+4 × 10^{7} CFU/kg of B. subtilis PB6; and E: CP challenge+6 × 10^{7} CFU/kg of B. subtilis PB6. The original strain of B. subtilis PB6 was obtained from Kemin China Technologies Co., Ltd., Zhuhai, China. Broilers were raised in a controlled environment and allowed ad libitum access to water and feed. Repetitions of different treatments were equally distributed among the cages as much as possible to reduce variations at the cage level. The entire experiment was divided into two phases: the non-CP challenge phase (d0–18) and the CP challenge phase (d18–26).

All diets were designed following the instructions of NRC (1994) and the Chinese chicken feeding standard (NY/T-33–2004) (Table 1). The CP challenge was performed on the basis of the study of Liu et al. [9].

A field strain of CP type A (CVCC2030) was cultured on tryptone-sulfite-cycloserine agar, and a single colony was then inoculated into a cooked meat medium and subsequently cultured in an incubator at 37°C for 8 hours. In the infected groups, chickens were orally inoculated with 1 ml bacterial solution containing 10^6 CFU/ml CP once a day from Day 19 to Day 25. Chickens in the basal diet group were subjected to the same gavage procedure described above but with a sterilized medium.

2.2. Growth Performance. The mortality rate was recorded throughout the experiment. Body weights of chickens were measured on Day 0, on Day 18, and on the last day (Day 26). Feed intake (FI), body weight gain (BWG), and the feed conversion ratio (FCR) were calculated and recorded for further analysis.

2.3. Lesion Score. Intestinal scoring was evaluated on Day 26. A randomly selected chicken of each repetition was killed by cervical dislocation and then underwent intestinal scoring. The intestines were cut open and scored for NE lesions.

<table>
<thead>
<tr>
<th>Ingredient (%)</th>
<th>Basal diet</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corn</td>
<td>57.52</td>
</tr>
<tr>
<td>Soybean meal (CP &gt; 46%)</td>
<td>36.20</td>
</tr>
<tr>
<td>Soy oil</td>
<td>2.14</td>
</tr>
<tr>
<td>Limestone</td>
<td>1.13</td>
</tr>
<tr>
<td>Dicalcium phosphate</td>
<td>1.97</td>
</tr>
<tr>
<td>Salt</td>
<td>0.35</td>
</tr>
<tr>
<td>Methionine (99%, DL-form)</td>
<td>0.19</td>
</tr>
<tr>
<td>Choline (50%)</td>
<td>0.25</td>
</tr>
<tr>
<td>Vitamin premix1</td>
<td>0.025</td>
</tr>
<tr>
<td>Mineral premix2</td>
<td>0.2</td>
</tr>
<tr>
<td>Ethoxyquin (66%)</td>
<td>0.03</td>
</tr>
<tr>
<td>Total</td>
<td>100.00</td>
</tr>
</tbody>
</table>

1Provided per kg of diet: vitamin premix (1 kg) contained the following: vitamin A, 50 MU; vitamin D₃, 12 MU; vitamin K₃, 10 g; vitamin B₆, 10 g; vitamin B₁₂, 0.1 g; vitamin E, 0.2 MU; biotin, 0.5 g; folic acid, 5 g; pantothenic acid, 50 g; niacin, 150 g copper, 4 g; zinc, 90 g; iron, 38 g; manganese, 46.48 g; selenium, 0.1 g; iodine, 0.16 g; cobalt, 0.25 g. 2Provided per kg of diet: 150 g copper, 4 g; zinc, 90 g; iron, 38 g; manganese, 46.48 g; selenium, 0.1 g; iodine, 0.16 g; cobalt, 0.25 g. 3Calculated value based on the analyzed data for the experimental diets.
2.4. Proinflammatory Cytokine and Tight Junction Protein Gene Expression. Jejunum samples were collected from broilers that were randomly selected from each replicate on Day 26 and stored at -80°C for RNA extraction. RNA extraction, reverse transcription, and quantification methods were performed according to Wang et al. [11]. In short, total RNA extraction was performed with a TRIzol reagent, and RNA quality and concentration were detected by a NanoDrop spectrophotometer (ND-2000 UV-Vis; Thermo Scientific Inc.). RNA reverse transcription and real-time fluorescence quantification were carried out with Takara reagents following the manufacturer’s instructions (Takara Biotechnology Inc.). An ABI 7500 Real-Time PCR System (Applied Biosystems) was used for real-time fluorescence quantitative detection. β-Actin was used as a reference gene to normalize the relative RNA expression. The primer sequences for β-actin, occludin, ZO-1, TLR4, IL-1β, TNF-α, and IFN-γ are listed in Table 2. Each sample was measured in triplicate, and the average value was calculated. The 2ΔΔCt method was used to calculate the relative mRNA expression of target genes [12].

2.5. Pyrosequencing of Ileal Microbiota. On Day 26, broiler ileal digesta were sampled. DNA was extracted from ileal digesta using a QIAamp® Fast DNA Stool Mini Kit (Qiagen Ltd., Germany) according to the guidelines. According to the specifications outlined by Illumina, all DNA samples were pretreated for MiSeq compositional sequencing. The V3-V4 region of the 16S rRNA gene was amplified, and Illumina index primers were attached in two separate PCRs.

FLASH software (v1.2.7) was used to generate raw tags [13]. Effective tags were obtained by the UCHIME algorithm [14] and QIIME (v1.7.0) analysis [15]. UPARSE software (v7.0.1001) was used to analyze sequences, and the sequences were clustered at 97% similarity as operational taxa (OTUs). The GreenGene database was used to compare sequences and classify the different classification levels of these sequences. Microbial diversity was detected through QIIME software and Python scripts.

2.6. Statistical Analysis. The data, including growth performance, lesion scores, and the gene expression of both intestinal tight junctions and proinflammatory cytokines collected for quantitative parameters, were analyzed using analysis of variance (ANOVA) under a completely randomized design. Significant differences among the treatments were measured using Duncan’s multiple comparison and were declared when P < 0.05.

3. Results

3.1. Effects of Bacillus subtilis PB6 on Growth Performance in Broilers Challenged with Clostridium perfringens. As shown in Table 3, before the birds were challenged by CP (Days 1–18), no differences were detected among the treatment groups (P > 0.05). However, during the CP challenge period, CP infection significantly reduced BWG and ADFI (P < 0.05) and tended to increase FCR (P = 0.062) compared to the control group. However, the addition of enramycin numerically increased the BWG of CP-infected chicks (P > 0.05). Moreover, the addition of a low dosage of B. subtilis PB6 increased the BWG (P < 0.05) and tended to increase the ADFI (P > 0.05) of CP-challenged chicks, while the addition of a high dosage of B. subtilis PB6 significantly increased the BWG and ADF of CP-challenged chicks (P < 0.05).

3.2. Effects of Bacillus subtilis PB6 on Intestinal Lesions and Gene Expression in Broilers Challenged with Clostridium perfringens. As shown in Table 4, CP infection significantly increased the intestinal lesion score compared to the control group (P < 0.05). However, dietary addition of enramycin and low and high dosages of B. subtilis PB6 significantly reduced the intestinal lesion score of CP-infected broilers (P < 0.05).

### Table 2: Sequences for real-time PCR primers.

<table>
<thead>
<tr>
<th>Genes</th>
<th>Primer sequence (5′–3′)</th>
<th>Accession no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-Actin</td>
<td>F: GAGAAATTTGTCGGTGACATCA R: CCTGAACCTCTATGCGCC</td>
<td>L08165</td>
</tr>
<tr>
<td>Occludin</td>
<td>F: ACGGCAGCATCCTCAGGAGGCAA R: GGCGAAAGCAGATGAGG</td>
<td>D21837.1</td>
</tr>
<tr>
<td>ZO-1</td>
<td>F: CTTCAAGGTTCTCTCTCCTCCTCCT R: CTGTTGTTGCTGCTGATC</td>
<td>XM_413773</td>
</tr>
<tr>
<td>TRL4</td>
<td>F: GTTCCTGTGAACTCCCAAA R: TATGGATGTGCCACCTTGGA</td>
<td>NM_001030693</td>
</tr>
<tr>
<td>IL-1β</td>
<td>F: ACTGGGCATCAAGGTCATGCA R: GGTAAGAGATGAAAGGCTGTC</td>
<td>NM_204524</td>
</tr>
<tr>
<td>TNF-α</td>
<td>F: GAGCGTTGACTTGCTGTC R: AAGCAACACACGCTATGCAC</td>
<td>NM_204267</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>F: TAACTCAAGTGGCAGTAGGTGGAG R: GACGCCATTGTGGTGGTAGG</td>
<td>NM_008337</td>
</tr>
</tbody>
</table>

1Abbreviation: ZO-1: zonula occludens-1; TRL4: Toll-like receptor-4; IL-1β: interleukin-1β; TNF-α: tumor necrosis factor-α; IFN-γ: interferon-γ.
Table 3: The effect of *B. subtilis* supplementation on growth performance and mortality in CP-challenged broilers.

<table>
<thead>
<tr>
<th>Treatment$^1$</th>
<th>Control group</th>
<th>CP-challenged model group</th>
<th>Antibiotics (positive control group)</th>
<th><em>B. subtilis</em> PB6 low-dosage group</th>
<th><em>B. subtilis</em> PB6 high-dosage group</th>
<th>SEM$^2$</th>
<th>P value$^3$</th>
</tr>
</thead>
<tbody>
<tr>
<td>d1–d18 nonchallenge phase</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BWG (g)</td>
<td>36.06</td>
<td>35.47</td>
<td>35.44</td>
<td>35.14</td>
<td>35.58</td>
<td>0.25</td>
<td>0.86</td>
</tr>
<tr>
<td>FI (g)</td>
<td>51.61</td>
<td>50.87</td>
<td>51.65</td>
<td>51.79</td>
<td>51.97</td>
<td>0.44</td>
<td>0.95</td>
</tr>
<tr>
<td>FCR</td>
<td>1.43</td>
<td>1.44</td>
<td>1.46</td>
<td>1.48</td>
<td>1.46</td>
<td>0.01</td>
<td>0.50</td>
</tr>
<tr>
<td>Mortality rate</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>1.00</td>
</tr>
<tr>
<td>d19–d26 challenge phase</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BWG (g)</td>
<td>66.12$^a$</td>
<td>54.95$^c$</td>
<td>59.21$^{bc}$</td>
<td>61.62$^{ab}$</td>
<td>62.86$^{ab}$</td>
<td>1.087</td>
<td>0.009</td>
</tr>
<tr>
<td>FI (g)</td>
<td>109.55$^a$</td>
<td>99.90$^{bc}$</td>
<td>98.35$^c$</td>
<td>106.30$^{ab}$</td>
<td>108.41$^a$</td>
<td>1.305</td>
<td>0.007</td>
</tr>
<tr>
<td>FCR</td>
<td>1.66</td>
<td>1.83</td>
<td>1.67</td>
<td>1.73</td>
<td>1.73</td>
<td>0.02</td>
<td>0.062</td>
</tr>
<tr>
<td>Mortality rate (%)</td>
<td>2.22</td>
<td>3.49</td>
<td>1.11</td>
<td>4.45</td>
<td>3.58</td>
<td>0.907</td>
<td>0.821</td>
</tr>
<tr>
<td>Overall</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BWG (g)</td>
<td>46.47$^a$</td>
<td>42.21$^c$</td>
<td>43.67$^{bc}$</td>
<td>44.31$^{abc}$</td>
<td>45.02$^{ab}$</td>
<td>0.394</td>
<td>0.004</td>
</tr>
<tr>
<td>FI (g)</td>
<td>71.66$^a$</td>
<td>67.84$^b$</td>
<td>67.81$^b$</td>
<td>70.66$^{ab}$</td>
<td>71.51$^a$</td>
<td>0.544</td>
<td>0.026</td>
</tr>
<tr>
<td>FCR</td>
<td>1.55</td>
<td>1.61</td>
<td>1.55</td>
<td>1.6</td>
<td>1.59</td>
<td>0.009</td>
<td>0.151</td>
</tr>
<tr>
<td>Mortality rate (%)</td>
<td>2.22</td>
<td>3.49</td>
<td>1.11</td>
<td>4.45</td>
<td>3.58</td>
<td>0.907</td>
<td>0.821</td>
</tr>
</tbody>
</table>

$^1$Treatment information: control group: basal diet; CP-challenged model group: basal diet and CP challenge; antibiotics (positive control group): CP challenge+10 mg/kg enramycin; *B. subtilis* PB6 low-dosage group: CP challenge+4 × 10$^7$ CFU/kg of feed *B. subtilis* PB6; *B. subtilis* PB6 high-dosage group: CP challenge+6 × 10$^7$ CFU/kg of feed *B. subtilis* PB6. BWG: body weight gain; FI: feed intake; FCR: feed conversion ratio.

$^2$Standard error of the means; n = 6 chickens/group.

$^3$Mean values within a column with unlike superscripts letters (a, b, and c) are significantly different (P < 0.05).
the OTUs were assigned and chimeras were removed, 3.3. The Quality of Gut Microbiota Sequencing Data. fed a diet with a high dosage of Bα expression (identi and the median read length was 427 bp. OTU numbers were Escherichia (4.24%), (1.44%) were the monas which are shown in Figure 1(d). CP challenge signi dominant phyla, accounting for 99.42% of all sequences in Phylum-level microbiota analysis Firmicutes showed that 4% abundance in the ileum. As shown in Figure 1(c), the groups. Supplementation with enramycin reduced dominant phyla, accounting for 99.42% of all sequences in OTUs were no signifi first group among all treatments (LDA score > 3) and tended to upregulate TNF-α expression (P < 0.05). Nevertheless, supplementation with enramycin upregulated occludin expression and downregulated TNF-α expression in the jejum of CP-infected birds (P < 0.05). Moreover, the infected broilers fed a diet with a low dosage of B. subtilis PB6 showed the highest ZO-1 mRNA expression among all groups (P < 0.05) and had relatively higher occludin expression than CP-infected birds (P < 0.05). Infected birds fed a diet with a high dosage of B. subtilis PB6 had lower expression of TNF-α (P < 0.05) and relatively higher occludin expression (P < 0.05) than infected birds fed a basal diet.

3.3. The Quality of Gut Microbiota Sequencing Data. After the OTUs were assigned and chimeras were removed, 1,965,036 effective sequences were obtained from 30 ileal samples, and 56,143 sequences were shared by a single sample. The read length ranged from 220 to 500 base pairs (bp), and the median read length was 427 bp. OTU numbers were identified. As shown in Figure 1(a), 109 OTUs were shared by five groups, and 112, 32, 111, 24, and 93 OTUs were exclusive in each group.

4. Discussion

Pathogenic bacteria, such as Clostridium perfringens (CP), can cause imbalances in animal homeostasis and damage to the body and severely affect animal growth performance [16]. A large amount of evidence has shown that probiotics are beneficial for improving the growth performance of animals under both the pathogen-infected and noninfected conditions, which may be due to the compounds secreted by probiotics, such as digestive enzymes, antibacterial substances, and/or other growth-promoting factors, such as short-chain fatty acids [17, 18]. As a widely used probiotic, Bacillus subtilis PB6 has been proven to improve broiler/animal feed intake, increase body weight, and reduce FCR

Table 4: Intestinal lesion score and relative mRNA expression of intestinal tight junction proteins and proinflammatory cytokines in broilers.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Control group</th>
<th>CP-challenged model group</th>
<th>Antibiotics (positive control group)</th>
<th>B. subtilis PB6 low-dosage group</th>
<th>B. subtilis PB6 high-dosage group</th>
<th>SEM²</th>
<th>P value³</th>
</tr>
</thead>
<tbody>
<tr>
<td>Occludin</td>
<td>1.11abc</td>
<td>0.50b</td>
<td>1.39a</td>
<td>0.75bc</td>
<td>0.65bc</td>
<td>0.093</td>
<td>0.009</td>
</tr>
<tr>
<td>ZO-1</td>
<td>1.04bc</td>
<td>1.43bc</td>
<td>1.68abc</td>
<td>2.54a</td>
<td>2.01ab</td>
<td>0.145</td>
<td>0.009</td>
</tr>
<tr>
<td>TRL4</td>
<td>1.1</td>
<td>1.06</td>
<td>0.98</td>
<td>1.38</td>
<td>1.24</td>
<td>0.069</td>
<td>0.335</td>
</tr>
<tr>
<td>IL-1β</td>
<td>1.32</td>
<td>2.04</td>
<td>1.47</td>
<td>2.14</td>
<td>2.87</td>
<td>0.199</td>
<td>0.106</td>
</tr>
<tr>
<td>TNF-α</td>
<td>1.06bc</td>
<td>1.45a</td>
<td>0.93b</td>
<td>1.33a</td>
<td>0.95b</td>
<td>0.083</td>
<td>0.022</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>1.12</td>
<td>1.83</td>
<td>1.15</td>
<td>1.68</td>
<td>1.76</td>
<td>0.137</td>
<td>0.289</td>
</tr>
<tr>
<td>Lesion score</td>
<td>0.00d</td>
<td>1.25a</td>
<td>0.33b</td>
<td>0.75b</td>
<td>0.66b</td>
<td>0.088</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

¹Treatment information: control group: basal diet; CP-challenged model group: basal diet and CP challenge; antibiotics (positive control group): CP challenge+10 mg/kg enramycin; B. subtilis PB6 low-dosage group; CP challenge+4×10⁷ CFU/kg of feed B. subtilis PB6; B. subtilis PB6 high-dosage group; CP challenge+6×10⁷ CFU/kg of feed B. subtilis PB6. ZO-1: zona occludens-1; TRL4: Toll-like receptor-4; IL-1β: interleukin-1β; TNF-α: tumor necrosis factor-α; IFN-γ: interferon-γ. ²Standard error of the means; n = 6 chickens/group. ³Mean values within a column with unlike superscripts letters (a, b, and c) are significantly different (P < 0.05). ⁰no gross lesions; 0.5 = severely congested serosa and mesenteric hyperemia; 1 = thin-walled and brittle intestines with small hemorrhagic spots (>5); 2 = small amounts of gas production and focal necrotic lesions; 3 = large amount of gas-filled intestines and necrotic plaques.

Compared to the control group, CP challenge led to a significant decrease in jejum mRNA expression of occludin (P < 0.05) and tended to upregulate TNF-α expression (P < 0.05). Nevertheless, supplementation with enramycin upregulated occludin expression and downregulated TNF-α expression in the jejum of CP-infected birds (P < 0.05). Moreover, the infected broilers fed a diet with a low dosage of B. subtilis PB6 showed the highest ZO-1 mRNA expression among all groups (P < 0.05) and had relatively higher occludin expression than CP-infected birds (P < 0.05). Infected birds fed a diet with a high dosage of B. subtilis PB6 had lower expression of TNF-α (P < 0.05) and relatively higher occludin expression (P < 0.05) than infected birds fed a basal diet.

Further statistics were carried out to identify differences in the ileal community at the genus level among the groups, which are shown in Figure 1(d). CP challenge significantly decreased the abundance of Clostridium XI, Streptococcus, and Staphylococcus in comparison with the control group (P < 0.05), while supplementation with enramycin and low-dosage B. subtilis PB6 raised these bacterial abundances to levels similar to those of nonchallenge birds (P > 0.05). The birds fed high-dosage B. subtilis PB6 had more Clostridium XI than the other groups (P < 0.05). LEfSe analysis showed that 18 differentially abundant bacterial clades were distributed to all taxonomic levels (LDA score > 3.0) among the 5 treatments (Figure 2(a)). The highest relative abundances of Clostridium XI, Peptostreptococcaceae, Desulfovibrionaceae, and Staphylococcus were indicated in the control group among all treatments (LDA score > 3.0). Moreover, supplementation with enramycin increased the relative abundances of Bonea and Xanthomonadaceae (LDA score > 3.0). Supplementation with a low dosage of B. subtilis PB6 increased Streptococcus abundance (LDA score > 3.0), while supplementation with a high dosage of B. subtilis PB6 increased Clostridia abundance (LDA score > 3.0). Figure 2(b) shows the ileal microbial alpha diversity. There were no significant differences in the diversity indexes (Shannon) among all groups (P > 0.05). Beta diversity was demonstrated via PCoA in Figure 2(c), showing no distinguishable clustering of the ileal samples in different treatments.

4. Discussion

Pathogenic bacteria, such as Clostridium perfringens (CP), can cause imbalances in animal homeostasis and damage to the body and severely affect animal growth performance [16]. A large amount of evidence has shown that probiotics are beneficial for improving the growth performance of animals under both the pathogen-infected and noninfected conditions, which may be due to the compounds secreted by probiotics, such as digestive enzymes, antibacterial substances, and/or other growth-promoting factors, such as short-chain fatty acids [17, 18]. As a widely used probiotic, Bacillus subtilis PB6 has been proven to improve broiler/animal feed intake, increase body weight, and reduce FCR
Figure 1: Continued.
In the present study, we also found that adding $4 \times 10^7$ and $6 \times 10^7$ CFU/kg $B. subtilis$ PB6 to the diet could mitigate the negative effects of CP infection on broiler BWG and FCR, particularly with the addition of a high dose. In addition, we found that $B. subtilis$ PB6 exerted a better growth-promoting effect on CP-infected broilers than enramycin, which is commonly used in CP prevention, ultimately confirming the growth-promoting effect of $B. subtilis$ PB6. However, other studies showed that the growth-promoting effect of $B. subtilis$ PB6 was not significant [21], and these inconsistent results across studies may be due to the breeding environment, animal species, additive dosage, or operating procedures.

CP can produce various toxins, bacteriocins, and collagennolytic enzymes after colonization [22]. These active substances affect tight junctions and their components, such as occludin and junction adhesion molecules (JAMs), by altering the transmembrane pores and extracellular matrix of intestinal cells, leading to compromised integrity of the lamina propria [23]. The above alterations are accompanied by activation of the mucosal immune response; subsequently, many proinflammatory cytokines are secreted, such as TNF-$\alpha$ and IL-1$\beta$ [24]. These cytokines can induce the rearrangement of tight junctions and damage the intestinal barrier, thereby causing a vicious cycle over the host and even a systemic infection [22]. In line with other studies [25–27], our results noted that CP infection caused severe physical damage to the intestine of broilers, significantly raising intestinal lesion scores, inhibited the gene expression of the intestinal TJ protein occludin, and upregulated the expression of the proinflammatory cytokine TNF-$\alpha$. These abnormal physiological alterations may be important factors in the reduction of growth performance of broilers infected with CP. Furthermore, we found that enramycin and $B. subtilis$ PB6 could variably increase the expression of the TJ proteins occludin and ZO-1 in CP-infected broilers and reduce the expression of the inflammatory factor TNF-$\alpha$. This indicates that the addition of enramycin and $B. subtilis$ PB6 can restore the intestinal physical barrier and reduce intestinal inflammation, thus helping to decrease the intestinal lesion scores and recover the physiological function of the damaged intestine. In agreement with our findings, Jayaraman et al. and Belote et al. reported that supplementation with $B. subtilis$ PB6 and enramycin prevented CP-induced NE and decreased lesion scores and also improved intestinal health in challenged broilers [8, 28]. Enramycin can kill pathogenic bacteria by directly inhibiting their cell wall formation, thereby reducing the damage caused by pathogens to the body [28]. However, in addition to competitive rejection, probiotics can also exert their growth-promoting effects through immune regulation, secretion of antibacterial molecules, and enhancement of the body’s antioxidant capacity. In this study, $B. subtilis$ PB6 exerted its immunomodulatory effect by downregulating the expression of TNF-$\alpha$ in the intestine of CP-infected broilers and simultaneously upregulating the expression of occludin and ZO-1. TNF-$\alpha$ is produced by activated monocytes/macrophages and is synthesized in large quantities during the acute phase of bacterial infection, subsequently promoting the activation of downstream immune cells, such as T cells, thus intensifying the inflammatory response and harming the host [29]. Similarly, recent studies have shown that $B. subtilis$ can reduce intestinal inflammation by modifying the polarization of macrophages, inhibiting the expression of TNF-$\alpha$, and thus protecting the body from bacterial infections [30]. As the main components of epithelial tight junctions, the improved mRNA expression of occludin and ZO-1 can enhance intestinal barrier function and protect intestinal health [31, 32]. Studies have also found that the culture supernatant of $B. subtilis$ can upregulate the expression of tight junction proteins and mucin 2 in HT-29 cells in vitro, but the specific metabolites are not yet known, and further exploration is needed [33].

The intestinal microbial community, which is regulated by many factors, such as food [34], age [35], and additives [36], is very important for the growth and health of broilers due to its ability to promote nutrient digestion and regulate the immune system [37]. In general, the diversity of gut microbiota is closely related to pathogen resistance. The intestinal microbiome can be affected by many factors, such as pathological conditions, antibiotic therapy, dietary supplementation, and housing environment [38]. Recently, Fasina
Figure 2: Effects of Bacillus subtilis PB6 on intestinal bacterial diversity in broilers challenged with Clostridium perfringens. (a) Diversity and composition of ileal microbiota (LEfSe score) in broilers. (b) Diversity and composition of ileal microbiota (circular cladogram) in broilers. (c) Alpha diversity analysis (Shannon) of ileal microbiota in broilers. (d) Beta diversity analysis (PCoA) of ileal microbiota in broilers. Treatment information: A: basal diet; B: basal diet and CP challenge; C: CP challenge+10 mg/kg enramycin (positive control group); D: CP challenge+4x10^7 CFU/kg of feed B. subtilis PB6 (PB6 low-dosage group); E: CP challenge+6x10^7 CFU/kg of feed B. subtilis PB6 (PB6 high-dosage group).
et al. [39] and Li et al. [40] reported that CP infection dramatically reduced the α-diversity index of the broiler intestinal microbial community. However, Xu et al. [41] and Zhang et al. [42] indicated the opposite result, which revealed that CP infection significantly increased the α-diversity index of the gut microbial community. Moreover, some studies found that CP infection did not affect either the α- or β-diversity index [43, 44], which is in agreement with the current results. Those authors considered that the discrepancy might be attributed to the following: (a) the different sections of the ileum in which the digesta were collected, (b) diverse CP strains and diet types, and (c) the different durations of CP challenge. Relevant references are limited, and further trials are required.

Studies have shown that the abundance of intestinal *Clostridium XI* is significantly increased, accompanied by a decreased gene expression of TNF-α and a decreased inflammation index in the colon after treatment with probiotics in a colitis mouse model [45]. Consistently, we found a higher abundance of *Clostridium XI* in the ileum of broilers in the control group, enramycin supplementation group, and low- and high-dosage *B. subtilis* PB6 supplementation groups, accompanied by a decrease in TNF-α expression and reduced intestinal lesions. Therefore, we speculate that a high abundance of *Clostridium XI* may inhibit intestinal inflammation. LEfSe analysis showed that *Streptococcus* was significantly enriched in the low-dose *B. subtilis* PB6 supplementation group. *Streptococcus* contains many probiotic strains, such as *Streptococcus thermophilus*. Recent studies have found that *Streptococcus thermophilus* can increase the expression of the tight junction proteins ZO-1 and ZO-2 in high-fat diet mice and maintain the expression of ZO-1 in a human intestinal epithelial cell line infected with *E. coli* [46–48]. Therefore, in this experiment, the increased expression of ZO-1 in the intestine of broilers in the low-dose *B. subtilis* PB6 supplementation group may be related to the increased abundance of *Streptococcus*. A previous study showed that *Bosea* contains strains that can secrete a variety of cellulolytic enzymes [49]. In this experiment, enramycin treatment significantly increased the abundance of *Bosea* in the intestine of CP-infected broilers. Thus, the ability of *Bosea* to decompose cellulose and improve the utilization of feed nutrients may be one of the reasons for the increased body weight of broilers in the enramycin group. *Staphylococcus*, as a conditionally pathogenic, is generally considered harmful to the host, but the reason for its decreased abundance in the ileum of CP-infected broilers remains unclear. This may be due to the occupying effect of CP that inhibits the reproduction of *Staphylococcus*. *Desulfovibrionaceae* and *Xanthomonadaceae* are currently less studied. However, one study found that *Xanthomonadales* is enriched in mice inoculated with Chinese propolis [50], but its function is unclear.

### 5. Conclusion

In summary, administration of *B. subtilis* PB6 can improve growth performance by enhancing intestinal barrier function, mitigating intestinal inflammation/lesions, and reshaping the ileal microbial composition in CP-challenged birds.

### Abbreviations

- **BWG**: Body weight gain
- **ADFI**: Average daily feed intake
- **ZO-1**: Zonula occludens-1
- **TRL4**: Toll-like receptor-4
- **IL-1β**: Interleukin-1β
- **TNF-α**: Tumor necrosis factor-α
- **IFN-γ**: Interferon-γ

### Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

### Conflicts of Interest

The authors declare that they have no conflicts of interest.

### Acknowledgments

This study was supported by the Shandong Provincial Key R&D Program (2019JZZY020602) and the China National Key R&D Program during the 13th Five-Year Plan Period (Grant No. 2017YFE0129900).

### References


[38] A. Corrigan, M. de Leeuw, S. Penaud-Frézet, D. Dimova, and R. A. Murphy, “Phylogenetic and functional alterations in bacterial community compositions in broiler ceca as a result of


